Interest in the potential medical use of naturally occuring chemicals in plants is increasing. This is intended to provide a comprehensive and up- to-date directory of plants and the substances found in them. It covers over 8000 plant species

This new edition offers a state-of-the-art and integrative vision of pharmacogenomics by exploring new concepts and practical methodologies focusing on disease treatments, from cancers to cardiovascular and neurodegenerative disorders and more. The collection of these theoretical and experimental approaches facilitates problem-solving by tackling the complexity of personalized drug discovery and development. Written by leading experts in their fields for the highly successful Methods in Molecular Biology series, the book aims to provide across-the-board resources to support the translation of pharmacogenomics into better individualized health care. Authoritative and up-to-date, Pharmacogenomics in Drug Discovery and Development, Third Edition aims to aid researchers in approaching the challenges in pharmacogenomics and personalized medicine with the introduction of these novel ideas and cutting-edge methodologies.

This edition includes both updates from the previous book titled Simulation for Designing Clinical Trials and new uses and issues concerning clinical trial simulations (CTS) along with case studies of how clinical trial simulations are being applied in various therapeutic and application areas. Importantly, the book expands on the utility of CTS for informing decisions during drug development and regulatory review. Each chapter was written by esteemed authors who have demonstrated expertise in state-of-the-art application of CTS. The target audience for this book includes not only researchers and scientists who wish to consider use of simulations in the design, analysis, or regulatory review and guidance of clinical trials, but also academic researchers and others working in drug development (e.g., clinicians, senior managers, project planning and regulatory affairs professionals). The focus is more on how the authors have used clinical trial simulation in decision processes instead of illustrating detailed technical aspects. This book is an information source that enables the reader to gain overall knowledge on how clinical trial simulations can be used to improve the efficiency, informativeness, speed and economy of model-based drug development and regulation.

Experience with Contraceptive Side Effects: Selection of a Contraceptive; P. Senanayake. Contraceptives and Women's Complaints; Y. Ahmed, S. Boccard. Variability in Steriod Pharmacokinetics: Population and Delivery Systems; J. Garza-Flores, et al. Pharmacology of Ethynyl Estrogens in Various Countries; J. Goldzeiher. Lessons from Endogenous Metabolism: Diet and Estrogen Metabolism; C. Longcope. Diet Circulating Estrogen Levels, and Estrogen Excretion; B. Goldin. Implications for Policy and Programs: Steroid Contraceptives and Women's Response; J. Kaufman. Bringing Client and Lifecycle Perspective to Scientific Evidence; J. Bruce. Future Research Directions: Regional Population Differences and Population Pharmacokinetics of Steroidal Contraceptives; S. GuoWei. Variability in Steroid Pharmacokinetics; L. Dorflinger. 14 additional articles. Index.

Covers fundamentals of peptide and protein drug delivery. This reference/text includes such considerations as synthesis, physical chemistry and biochemistry, analysis, proteolytic and transport constraints, pharmacokinetics, and pharmacodynamics as well as bioavailability from routes of administration.

Highlighting the current developments and future directions in GABA and glycine research, this volume covers the major inhibitory neurotransmitters from the molecular mechanisms of signal transduction to their role in health and disease. It is of topical importance because these neurotransmitters are essential for brain function and therapy of diseases such as anxiety disorders, insomnias, epilepsy, depression, spasticity, and memory deficits. Distinguished scientists at the forefront of research contributed reviews on the role of these transmitters in governing neuronal networks, their signalling pathways, their receptors, the pharmacology of GABA A- and GABA B- and GABA C-receptors as well as of GABA- and glycine-transporters, and their role in disease. The volume serves as reference for pharmacologists/toxicologists, neuroscientists, neurologists and psychiatrists.

This book is focused on marine based biomedical carriers for delivery of therapeutics. Marine biomaterials and bio-based carriers show wide applications in pharmaceutical as well as biomedical fields for delivery of small and large molecules. Biomaterial-based composites, scaffolds or matrix systems are promising systems for controlled and prolonged release of drug in target site and control the premature release of drugs or bioactive compounds. This book discusses the targeted delivery of drugs and therapeutic applications. It also describes the use of marine biopolymers in cancer therapy. Different chapters describe the tissue engineering techniques to develop these carriers. The marine biomaterial-based systems are widely used for tissue engineering, and biomedical imaging. This book is meant for industry experts, students and researchers in the area of pharmaceutical sciences, biomedical engineering and material science and pharmacology.

The origins of tinnitus and the development of effective treatments to treat tinnitus have puzzled scientists and clinicians for centuries. Now ground breaking research is beginning to unlock its secrets. The Behavioral Neuroscience of Tinnitus provides critical and comprehensive discussions of the most recent developments in behavioral neuroscience research of tinnitus. Each chapter represents the most important contemporary account of the subject, with an emphasis on preclinical and clinical trials for the development of new diagnostics and therapeutics. New and emerging innovative approaches are covered whenever possible. Six topics are discussed in detail in this volume, which provide new insights in the etiology and mechanisms of tinnitus, new biomarkers towards objective and reliable diagnosis of tinnitus, pharmacological approaches towards curing tinnitus, bioengineering advances towards developing effective medical devices, as well as the latest in psychotherapy methods. The reviews in the volume expose researchers and clinicians, both new and experienced, to exciting advancements and state-of-the-art developments from preeminent researchers in the field of tinnitus.

Chemotherapy is one of the major treatment options for cancer patients; however, the efficacy of chemotherapeutic management of cancer is severely limited by multidrug resistance, in that cancer cells become simultaneously resistant to many structurally and mechanistically unrelated drugs. In the past three decades, a number of mechanisms by which cancer cells acquire multidrug resistance have been discovered. In addition, the development of agents or strategies to overcome resistance has been the subject of intense study. This book contains comprehensive and up-to-date reviews of multidrug resistance mechanisms, from over-expression of ATP-binding cassette drug transporters such as P-glycoprotein, multidrug resistance-associated proteins, and breast cancer resistance p- tein to the drug ratio-dependent antagonism and the paradigm of cancer stem cells. The book also includes strategies to overcome multidrug resistance, from the development of compounds that inhibit drug transporter function to the modulation of transporter expression. In addition, this book contains techniques for the detection and imaging of drug transporters, methods for the investigation of drug resistance in animal models, and strategies to evaluate the efficacy of resistance reversal agents. The book intends to provide a state-of-the-art collection of reviews and methods for both basic and clinician investigators who are interested in cancer multidrug resistance mechanisms and reversal strategies. Tianjin, China Jun Zhou v Contents Preface. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . v Contributors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ix 1 Multidrug Resistance in Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Bruce C. Baguley 2 Multidrug Resistance in Oncology and Beyond: From Imaging of Drug Efflux Pumps to Cellular Drug Targets . . . . . . . . . . . . . . . . . . . . . . . . . .

This volume records the proceedings of the Workshop on Advanced Meth ods of Pharmacokinetic and Pharmacodynamic Systems Analysis, organized by the Biomedical Simulations Resource in May 1990. The meeting brought together over 120 investigators from a number of disciplines, including clinical pharmacology, clinical pharmacy, pharmaceutical science, biomathematics, statistics and biomed ical engineering with the purpose of providing a high-level forum to facilitate the exchange of ideas between basic and clinical research scientists, experimentalists and modelers working on problems in pharmacokinetics and pharmacodynamics. It has been my experience that in many areas of biomedical research, when a meeting of this type is held, the general attitude of those experimentalists willing to attend is one of extreme skepticism: as a group they feel that mathematical modeling has little to offer them in furthering their understanding of the particular biological processes they are studying. This is certainly not the prevailing view when the topic is pharmacokinetics and drug response. Quite the contrary, the use of mathemati cal modeling and associated data analysis and computational methods has been a central feature of pharmacokinetics almost from its beginnings. In fact, the field has borrowed techniques of modeling from other disciplines including applied math ematics, statistics and engineering, in an effort to better describe and understand the processes of drug disposition and drug response."

Measured by any criteria, research in chronobiology in general and chronopharmacology in particular has expanded rapidly in recent years. This expansion has been paralleled by an increasing recognition by those outside the field of the relevance and significance of recent developments in chronobiology. Advances in two areas have been chiefly responsible. First, application of the full range of modern techniques in behavioral, neurochemical, and molecular biology have greatly improved our understanding of basic clock mechanisms. In several species the genetic basis of the circadian clock is being progressively delineated. A complete picture of the neurochemical and neuroanatomical structure of the mammalian clock is emerging and the complex pattern of control mechanisms involving endogenous clock mechan isms and photic and nonphotic zeitgebers is being built up as a result of behavioral studies. Secondly, in parallel with these exciting developments in basic science, clinical applications are being convincingly demonstrated in the general fields of pharmacology and medicine as well as in specific areas, e.g., jet lag, shiftwork maladaption syndrome, blindness, and cardiovascular system. It is therefore an opportune time to review progress in the field of chronopharmacology and to introduce some of the exciting developments and prospects to a readership beyond the confines of the chronobiological cognoscenti. This volume is therefore aimed primarily at the pharmacologist - whether basic, applied, or clinical-who is not a specialist in chronobiology."

This volume continues to document and summarize developments, trends, and emergent interdisciplinary research in behavioral psychopharmacology. For researchers and graduate students in psychopharmacology, behavioral pharmacology, toxicology, and the neurosciences. This seventh volume continues to document and summarize developments, trends, and emergent interdisciplinary research in behavioral psychopharmacology. For researchers and graduate students in psychopharmacology, behavioral pharmacology, toxicology, and the neurosciences. This is the latest volume in a series that continues to document and summarize developments, trends, and emergent interdisciplinary research in behavioral pharmacology, psychopharmacology, and the neurosciences. The chapters, written by authorities in their respective research areas, provide up-to-date examination and analysis of dominant evolving research areas.
Designed as a resource text for professionals, as well as a supplementary text for upper level undergraduate and graduate students of behavioral pharmacology, psychopharmacology, psychobiology, and related fields, this book, like the others in the "Advances in Behavioral Pharmacology Series," provides comprehensive coverage unavailable elsewhere.

This book provides the pharmaceutical formulator with the fundamental understanding necessary to prepare efficacious topical drug delivery formulations that have both chemical and physical stability and that are cosmetically acceptable and preferably cosmetically elegant.

The CTBN volume Therapeutic Applications of Dopamine D3 Receptor Function reviews the state of the knowledge on the dopamine D3 receptor and its role in human behavior and disease (i.e.: neuropsychiatric illnesses including schizophrenia, mood disorders, Parkinson's disease, restless legs syndrome, addictions and substance use disorders). The volume is written by leading experts across multidisciplinary areas (imaging, biobehavioral testing and clinical trials, preclinical models / molecular pharmacology) converging on the therapeutic implications / potential of the D3 receptor.The D3 dopamine receptor is a member of the D2-like family of G protein-coupled receptors. It was cloned and characterized almost 25 years ago. A key feature of the D3 dopamine receptor system, which has attracted considerable attention, is its anatomical localization remarkably restricted to the limbic circuitry. This has spurred the hypothesis that D3 involvement could contribute to the pathophysiology of neuropsychiatric disorders (or to some features of neuropsychiatric disorders), including but not limited to psychosis, addictions and substance abuse, mood and movement disorders.

This book provides an overview of nanoparticle production methods, scale-up issues drawing attention to industrial applicability, and addresses their successful applications for commercial use. There is a need for a reference book which will address various aspects of recent progress in the methods of development of nanoparticles with a focus on polymeric and lipid nanoparticles, their scale-up techniques, and challenges in their commercialization. There is no consolidated reference book that discusses the emerging technologies for nanoparticle manufacturing. This book focuses on the following major aspects of emerging technologies for nano particle manufacturing. I. Introduction and Biomedical Applications of NanoparticlesII. Polymeric Nanoparticles III. Lipid NanoparticlesIV. Metallic Nanoparticles V. Quality Control for NanoparticlesVI. Challenges in Scale-Up Production of Nanoparticles VII. Injectable Nanosystems VIII. Future Directions and ChallengesLeading scientists are selected as chapter authors who have contributed significantly in this field and they focus more on emerging technologies for nanoparticle manufacturing, future directions, and challenges.

The fact that tumors are composed of both tumor cells and host cells has long been known. These tumor-associated cells include vascular endothelial cells and pe- cytes, as well as inflammatory cells such as neutrophils, monocytes, macrophages, mast cells and eosinophils, and lymphocytes. The tumor cells also interact with stromal cells and with elements of the tissue extracellular matrix. What has been less appreciated is the role that these cells could have in modulating the growth, invasion, and metastasis of the tumor. Early on, the elements of what we now call the tumor microenvironment were considered to be more or less innocent bysta- ers to the role of the tumor cells as they grew and invaded local sites. Today, there is an increased understanding of the critical role of the tumor microenvironment as dramatically influencing the course of tumor development and dissemination. This volume represents a superb compilation of the latest thoughts and data regarding the role of each essential component of the tumor microenvironment in cancer development and progression. Perhaps, the earliest recognition of the role of nonmalignant cells as cancer re- lators was the recognition that lymphocytes can participate in what was termed "immune surveillance" in the 1960s. Our understanding of tumor immunity has improved markedly since then, and there are now successful clinical studies sh- ing the potential use of immune-based therapies in cancer treatment.

This volume reviews the current state of research within the behavioral pharmacology of 5-HT. The book opens exciting new approaches to the interdisciplinary study of behavior and pharmacology with special reference to ethology, endocrinology, neuroanatomy and comparative aspects of drug action, and notes new developments in therapeutic drugs of the future.

A compendium of optimized methods to measure type I interferon efficacy as an antiproliferative or an antiviral agent. These cutting-edge techniques range from the simple to the highly complex and serve to illuminate the signaling cascades and the activation of enzymatic pathways prompted by interferon. The protocols follow the successful Methods in Molecular Medicine series format, each offering step-by-step laboratory instructions, an introduction outlining the principle behind the technique, lists of the necessary equipment and reagents, and tips on troubleshooting and avoiding known pitfalls.
State-of-the-art and highly practical, Interferon Methods and Protocols offers researchers powerful tools not only to ascertain the functions of IFN-stimulatory gene products, but also to identify additional molecular pathways that will clarify our understanding of the many biological events influenced by IFNs."

This book describes different aspects of characterization and detection of nanomaterials in liquid disperse systems, such as suspensions, emulsions and suspoemulsions. Natural and technical particulate nanomaterials (NMs) are often present in formulations and products consisting of several disperse phases and complex dispersion media. Specific interfacial properties of the particles, their interactions with each other and with the dispersion medium, have to be considered. For example, the interfacial properties determine whether the particles tend to be arranged in aqueous or lipid phases or at their phase boundaries. The interfacial properties are significantly influenced by the adsorption of dissolved species, i.e., they depend on the composition of the dispersion medium. This poses great challenges for the characterization of these nanoparticle systems and requires adequate preparation methods. The nanoparticle measurement techniques aim at a deep physico-chemical understanding of the dispersity state of nanoparticle systems. Since the dispersity state of nanoparticle systems in an application usually does not correspond to their original manufacturing process, the formulation of new or improved product properties is of decisive importance. The characterization of nanoparticles in complex formulations or matrices requires an adequate sample preparation based on an existing or yet to be developed Standard Operating Procedure (SOP). The structure of the SOPs includes the dispersion regulations, which are of essential importance for comparing reproducible results of nanoparticle measurement with respect to comparability and transferability worldwide. The aim is to separate and isolate relevant NMs with knowledge of the interrelationships.

Considerable progress has been made in our healthcare system, in particular with respect to sensitive diagnostic tools, reagents and very effective and precise drugs. On the other hand, high-throughput screening technology can screen vast numbers of compounds against an array of targets in a very short time, and leads thus - tained can be further explored. In developing countries, the exploding population exerts pressure not only on natural resources but also on the human population - self, whose members strive to become successful and advance in society. This leads to increased blood pressure, anxiety, obesity-associated lipid disorders, cardiov- cular diseases and diabetes. Most of these diseases result in disturbed family life, including sexual behaviour. Despite technological developments, herbal drugs still occupy a preferential place in a majority of the population in the Third World and terminal patients in the West. Herbal drugs, in addition to being cost effective and easily accessible, have been used since time immemorial and have passed the test of time without having any side effects. The multitarget effects of herbs (holistic approaches) are the fun- mental basis of their utilization. This approach is already used in traditional systems of medicine like Ayurveda, which has become more popular in the West in recent years. However, the integration of modern science with traditional uses of herbal drugs is of the utmost importance if ones wishes to use ancient knowledge for the betterment of humanity.

This volume provides a comprehensive overview of recent advances in targeting glutamate signaling for the treatment of major psychiatric and neurological disorders. It draws on the latest findings in glutamate neurobiology and offers valuable insights into the application of translational principles in neuroscience drug discovery and development. In each chapter, glutamate as a neurotransmitter, its receptors and transporters, and their interplay with other neurotransmitters and neurotrophic factors, are discussed in the context of a specific, highly prevalent and disabling CNS disease. Most recent and detailed information is provided on Ischemic Stroke, Chronic Stress, Major Depressive Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD), Posttraumatic Stress Disorder (PTSD), Alzheimer's Dementia, Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD), Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple Sclerosis, Parkinson's Disease, Attention Deficit Hyperactivity Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders. Moreover, the book includes an extensive overview of glutamatergic treatments already available on the market, and those which are currently in pharmaceutical drug development pipelines. The primary beneficiaries will be neurology and psychiatry specialists and residents, neuroscientists, neuropharmacologists, pharmaceutical industry and clinical research organization professionals, academics, and clinicians working with psychiatric and neurological patients with comorbidities such as cardiologists, pulmonologists, and endocrinologists. This book will also appeal to psychiatry and neurology subspecialists and clinicians working in neuroscience labs seeking an easy-to-understand yet comprehensive overview of contemporary evidence-based clinical insights backed by basic science (preclinical) research evidence. Given its scope, the book is also a unique and indispensable resource for both preclinical and clinical neuroscientists, medical advisors, and clinical research specialists in the pharmaceutical industry. In addition, it will appeal to neuroscience and neuropsychopharmacology students and guide them through the complexities of glutamate involvement in the pathophysiology of the most common debilitating brain diseases with high unmet medical needs.

The study of drug effects on behavior is truly a confluence of streams of neuroscience research. The material in this volume covers a broad range of methodology representative of practically the entire scope of psychopharmacology for conscious animals. The contributions in this book represent careful evaluations by experts who were invited to participate because of their excellent practical application of research design and methodology. In each case, a particularly useful and well-written contribution has been forthcoming, and should serve either as a valuable introduction to developing researchers or as a practical reference to those active in the field. The material is arranged in an intuitive hierarchy. This arrangement is based on what are ostensibly increasing levels of integrated activity of the nervous system and, therefore, increasing levels of behavioral integration. Nevertheless, as all of the areas covered are rather detailed in their levels of intrinsic complexity, this arrangement of chapters does not imply successively more intricate problems. The reader will find some overlap between chapters, but little interdependence, i.e., each may be read as a separate or as an integral part of the volume.

Essentials of Industrial Pharmacy is an attempt to comprehensively present, in a single book, various pharmaceutical processes and equipment that are frequently used for production of pharmaceutical dosage forms, along with quality control tests of these dosage forms. Pictorial/graphical illustrations provide easier understanding of complex pharmaceutical concepts, manufacturing processes of pharmaceutical dosage forms. Since it is imperative for pharmacy students to have a clear understanding of the basic concepts used in development of drugs into suitable and stable dosage forms. This book offers a wealth of information regarding basic aspects of pharmaceutical processes and dosage forms, in a single book, for undergraduate pharmacy students or science students (with no pharmacy background) intended to work in the pharmaceutical Industry.